BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study

Blood

Volumn 91, Issue 4, 1998, Pages 1391-1398

  Winter, Jane N ^a   Andersen, Janet ^b   Reed, John C ^b   Krajewski, Stanislaw ^b   Variakojis, Daina ^b   Bauer, Kenneth D ^b   Fisher, Richard I ^b   Gordon, Leo I ^b   Oken, Martin M ^b   Jiang, Shuwei ^b   Jeffries, David ^b   Domer, Peter ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; ONCOGENE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032520006     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.4.1391     Document Type: Article

References (60)

1. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386, 1996
2. Reed JC: BCL-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451, 1995
3. Tsujimoto T. Finger LR, Yunis J, Nowell PC, Croce CM: Cloning the chromosome breakpoint of neoplastic B-cells with the t(14; 18) chromosome translocation. Science 226:1097, 1984
4. H on chromosome 14 and near a transcriptional unit on 18. Cell 41:899, 1985
5. Cleary ML, Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439, 1985
6. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Amesen M: Multiple recurrent genomic defects in follicular lymphoma. N Engl J Med316:79, 1987
7. Weiss LM, Warnke RA, Sklar J, Cleary ML: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med317:1185, 1987
8. Zutter M, Hockenbery D, Silverman G, Korsmeyer SJ: Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 78:1062,1991
9. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265, 1996
10. Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 88:1046, 1996
11. Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JHJM, de Jong D, Kluin PM: Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: A population based study. J Clin Oncol 14:2131, 1996
12. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244, 1997
13. Braylan RC: Lymphomas, in Bauer KD, Duque RE, Shankey TV (eds): Row Cytometry: Principles and Applications. Baltimore, MD, Williams & Wilkins, 1993, p 203
14. Duque RE, Andreef M, Braylan RC, Diamond LW, Peiper SC: Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 14:492, 1993
15. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer B, Tubbs RR, Gaynor ER, Fisher RI: Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83:1460, 1994
16. Winter JN, Andersen J, Variakojis D, Gordon LI, Fisher RI, Oken MM, Neiman RS, Jiang S, Bauer KD: Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Blood 88:3919, 1996
17. Linette GP, Li Y, Roth K, Korsmeyer SJ: Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA 93:9545, 1996
18. Mazel S, Burtrum D, Petrie HT: Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J Exp Med 183:2219, 1996
19. Borner C: Diminished cell proliferation associated with the death protective activity of Bcl-2. J Biol Chem 271:12695, 1996
20. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, O'Connell M: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342, 1992
21. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
22. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333,1983
23. Bauer KD, Merkel DE, Winter JN, Marder RJ, Hauck WW, Wallmark CB, William TJ, Variakojis D: Prognostic implications of ploidy and proliferative activity in diffuse, large cell lymphomas. Cancer Res 46:3173, 1986
24. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM: Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265:472, 1991
25. Crescenzi M, Seto M, Herzig GP, Weiss PD, Griffith RC, Korsmeyer SJ: Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 85:4869, 1988
26. Ngan B-Y, Nourse J, Cleary M: Detection of chromosomal translocation of t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 73:1759, 1989
27. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC: Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 145:515, 1994
28. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471, 1995
29. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing for ordered categorical data. Biometrics 40:819, 1984
30. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982
31. Segal G, Scott M, Jorgensen T, Braylan RC: Standard polymerase chain reaction analysis does not detect t(14;18) in reactive lymphoid hyperplasia. Arch Path Lab Med 118:791, 1994
32. Barrans S, Randerson J, Evans P, Blythe D, Shiach C, Child JA, Morgan G, Jack AS: Heterogeneity in cell proliferation and expression of p53 and bcl-2 during the indolent phase of germinal center cell lymphoma: An explanation for clinical variability. Br J Haematol 90:830, 1995
33. Leoncini L, Del Vecchio MT, Megha T ,Barbini P, Galieni P, Pileri S, Savattini E, Gherlinzoni F, Tosi P, Kraft R, Cottier H: Correlations between apoptotic and proliferative indices in malignant and non-Hodgkin's lymphomas. Amer J Pathol 142:755, 1993
34. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn J, Korsmeyer S: Bcl-2 immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 57:79, 1989
35. Marvel J, Perkins GR, Lopez Rivas A, Collins MKL: Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness to IL-3 stimulation of proliferation. Oncogene 9:1117, 1994
36. O'Reilly LA, Huang DC, Strasser A: The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 15:6979, 1996
37. Du M, Singh N, Husseuin A, Isaacson PG, Pan L: Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol 178:379, 1996
38. Leoncini L, Del Vecchio MT, Spina D, Megha T, Barbini P, Sabattini E, Pileri S, Tosi P, Kraft R, Laissue JA, Cottier H: Presence of the bcl-2 protein and apoptosis in non-Hodgkin lymphomas with diffuse growth pattern. Int J Cancer 61:826, 1995
39. Del Vecchio MT, Leoncini L, Buerki K, Kraft R, Megha T, Barbini P, Tosi P, Cottier H: Diffuse centrocytic and/or centroblastic malignant non-Hodgkin's lymphomas: Comparison of mitotic and pyknotic (apoptotic) indices. Int J Cancer 47:38, 1991
40. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601, 1997
41. Grierson HL, Wooldridge TN, Hess M, Ratashak A, Wooldridge L, Fordyce-Boyer R, Bast M, Armitage JO, Weisenburger DD, Sanger WG: Proliferative fraction and DNA content are lower in B-cell non-Hodgkin's lymphomas with the t(14;18). Leuk Lymphoma 19:253, 1995
42. Srigley J, Barlogie B, Butler JJ, Osborne B, Blick M, Johnston D, Kantarjian H, Reuben J, Batsakis J, Freireich E: Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry. Blood 65:1090, 1985
43. Weiss LM, Wamke RA, Sklar J, Cleary ML: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med317:1185, 1987
44. Levine EG, Arthur DC, Frizzera G, Peterspn BA, Hurd DD, Bloomfield CD: There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood 66:1414, 1985
45. Gulley ML, Dent GA, Ross DW: Classification and staging of lymphoma by molecular genetics. Cancer 69:1600, 1992 (suppl 6)
46. Matolcsy A, Casali P, Warnke RA, Knowles DM: Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88:10, 1996
47. McConkey DJ, Chandra J, Wright S, Funkett W, McDonnell TJ, Reed JC, Keating M: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156:2624, 1996
48. Hanada M, Aime-Sempe C, Sato T, Reed JC: Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 270:11962, 1995
49. Brady HJM, Gil-Gomez G, Kirberg J, Berns AJM: Bax-alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J 15:6991,1996
50. Karlsen F, Kalantari M, Chitemerere M, Johansson B, Hagmar B: Modifications of human and viral deoxyribonucleic acid by formaldehyde fixation. Lab Invest 71:604, 1994
51. Coad JE, Olson DJ, Lander TA, McGlennen RC: Molecular assessment of clonality in lymphoproliferative disorders: I. Immunoglobulin gene rearrangements. Mol Diagn 4:335, 1996
52. Ladanyi M, Wang S: Detection of rearrangement of BCL2 major breakpoint region in follicular lymphomas, correlation of polymerase chain reaction results with Southern blot analysis. Diagn Mol Pathol 1:31, 1992
53. Horsman DE, Gascoyne RD, Coupland RW, Goldman AJ, Adomat SA: Comparison of cytogenetic analysis, Southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol 103:472, 1995
54. Lui J, Johnson RM, Traweek ST: Rearrangement of the BCL-2 gene in follicular lymphoma, detection by PCR in both fresh and fixed tissue samples. Diagn Mol Pathol 2:241, 1993
55. Yunis JJ, Mayer MB, Arnesen MA, Aeppli DP, Oken MM. Frizzera G: Bcl-2 and other genomic alteration in the prognosis of large-cell lymphoma. N Engl J Med 320:1047, 1989
56. Jacobson JO, Wilkes BM, Kwiatkowski DJ, Medeiros LJ, Aisenberg AC, Harris NL: Bcl-2 rearrangement in de novo diffuse large cell lymphomas. Cancer 72:231, 1993
57. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S: Clinical significance of bcl-2 MBR gene rearrangement and protein expression in diffuse large cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 12:149, 1994
58. Piris MA, Pezella F, Martinex-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F: p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337, 1994
59. Shimamura A, Fisher DE: p53 in life and death. Clin Cancer Res 2:435, 1996
60. Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali G, Rahal D, Pedron S, Benedetti A, Scardoni M, Macri E, Lestani M, Menestrina F, Pizzolo G, Scarpa A: p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: A potential marker of p53 tumor-suppressor gene function. Blood 88:4012, 1996